• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期侵袭性B2胸腺瘤患者在CAP-恩度联合治疗后取得了积极疗效。

Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy.

作者信息

Zhang Min, Zhang Jingjing, Zhao Kelei, Yuan Xiaohan, Zhang Jinghang, Liu Yanting, Lu Ping

机构信息

Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.

Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.

出版信息

Clin Respir J. 2025 Jun;19(6):e70081. doi: 10.1111/crj.70081.

DOI:10.1111/crj.70081
PMID:40544865
Abstract

This case report features a patient with an invasive thymoma. The patient presented with an anterior mediastinal mass that invaded the left brachiocephalic trunk vein, resulting in the formation of a carcinoma thrombus in the right atrium, superior vena cava, left brachiocephalic trunk vein, and left internal jugular vein (Masaoka stage IV). No indication for surgery was assessed by surgical consultation. After six cycles of chemotherapy and chest radiotherapy, the tumor size decreased from 72.43 to 24 mm, showing a significant improvement in patient efficacy. After a follow-up of 50 months, the patient remained well, without local recurrence or distal metastasis, and maintained a partial response (PR).

摘要

本病例报告介绍了一名侵袭性胸腺瘤患者。该患者表现为前纵隔肿块,侵犯了左头臂干静脉,导致右心房、上腔静脉、左头臂干静脉和左颈内静脉形成癌栓(Masaoka 分期 IV 期)。经外科会诊评估,无手术指征。经过六个周期的化疗和胸部放疗后,肿瘤大小从 72.43 毫米缩小至 24 毫米,患者疗效显著改善。经过 50 个月的随访,患者情况良好,无局部复发或远处转移,维持部分缓解(PR)。

相似文献

1
Patient With Advanced Aggressive B2 Thymoma Achieved Positive Outcomes Post CAP-Endostar Combination Therapy.晚期侵袭性B2胸腺瘤患者在CAP-恩度联合治疗后取得了积极疗效。
Clin Respir J. 2025 Jun;19(6):e70081. doi: 10.1111/crj.70081.
2
Effectiveness of Adjuvant Chemo- and Radiotherapy in Thymic Carcinoma Stage II: A Systematic Review and Meta-Analysis.II期胸腺癌辅助放化疗的疗效:一项系统评价和荟萃分析
Cancer Control. 2024 Jan-Dec;31:10732748241292781. doi: 10.1177/10732748241292781.
3
Synchronous HPV-related Tonsillar Squamous Cell Carcinoma and Type AB Thymoma: Successful Cancer Treatment Complicated by Fatal COVID-19 Infection.同步发生的人乳头瘤病毒相关扁桃体鳞状细胞癌和AB型胸腺瘤:成功的癌症治疗并发致命的新型冠状病毒肺炎感染
In Vivo. 2025 Jul-Aug;39(4):2085-2090. doi: 10.21873/invivo.14003.
4
The management of thymoma: a systematic review and practice guideline.胸腺瘤的管理:一项系统综述与实践指南
J Thorac Oncol. 2009 Jul;4(7):911-9. doi: 10.1097/jto.0b013e3181a4b8e0.
5
Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series.病例报告:替雷利珠单抗联合化疗对晚期胸腺上皮肿瘤的强效持久反应:病例系列
Front Immunol. 2025 May 27;16:1516297. doi: 10.3389/fimmu.2025.1516297. eCollection 2025.
6
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline.胸腺上皮肿瘤患者的手术、放疗及全身治疗:临床实践指南
J Thorac Oncol. 2022 Nov;17(11):1258-1275. doi: 10.1016/j.jtho.2022.08.007. Epub 2022 Aug 27.
7
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review.胸腺上皮肿瘤患者的手术、放疗及全身治疗:一项系统评价
J Thorac Oncol. 2023 Mar;18(3):299-312. doi: 10.1016/j.jtho.2022.10.016. Epub 2022 Nov 4.
8
Survival Impact of Adjuvant Radiation Therapy in Masaoka Stage II to IV Thymomas: A Systematic Review and Meta-analysis.辅助放疗对 Masaoka 分期 II 至 IV 期胸腺瘤患者生存的影响:系统评价和荟萃分析。
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1129-36. doi: 10.1016/j.ijrobp.2016.01.007. Epub 2016 Jan 14.
9
Analysis of surgical treatment of Masaoka stage III-IV thymic epithelial tumors.MasaokaⅢ-Ⅳ期胸腺上皮肿瘤的外科治疗分析
Gen Thorac Cardiovasc Surg. 2018 Dec;66(12):731-735. doi: 10.1007/s11748-018-0996-9. Epub 2018 Aug 21.
10
Systemic treatments for thymoma and thymic carcinoma: A systematic review.胸腺瘤和胸腺癌的系统治疗:系统评价。
Lung Cancer. 2018 Dec;126:25-31. doi: 10.1016/j.lungcan.2018.10.018. Epub 2018 Oct 18.

本文引用的文献

1
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501.S-1 联合顺铂同期放化疗治疗局部晚期胸腺癌:LOGIK1605/JART-1501 研究方案。
Thorac Cancer. 2020 Mar;11(3):693-696. doi: 10.1111/1759-7714.13319. Epub 2020 Feb 5.
2
Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets.胸腺瘤基因表达谱的改变:遗传差异和潜在的新靶点。
Thorac Cancer. 2019 May;10(5):1129-1135. doi: 10.1111/1759-7714.13053. Epub 2019 Apr 1.
3
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
吉西他滨和顺铂联合恩度治疗晚期胸腺瘤和胸腺癌的疗效和毒性。
Thorac Cancer. 2019 Jan;10(1):17-23. doi: 10.1111/1759-7714.12891. Epub 2018 Nov 9.
4
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.晚期胸腺癌的系统治疗:来自 RYTHMIC 前瞻性队列研究的见解。
J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.
5
Rare Thymoma Metastases to the Spine: Case Reports and Review of the Literature.罕见胸腺瘤脊柱转移:病例报告及文献综述
World Neurosurg. 2018 Feb;110:423-431. doi: 10.1016/j.wneu.2017.11.161. Epub 2017 Dec 6.
6
Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database.局部晚期胸腺瘤的多模态治疗:一项来自欧洲胸外科医师协会数据库的倾向评分匹配队列研究。
J Thorac Cardiovasc Surg. 2016 Jan;151(1):47-57.e1. doi: 10.1016/j.jtcvs.2015.08.034. Epub 2015 Aug 15.
7
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.《2015年世界卫生组织肺、胸膜、胸腺和心脏肿瘤分类》简介
J Thorac Oncol. 2015 Sep;10(9):1240-1242. doi: 10.1097/JTO.0000000000000663.
8
Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.卡铂和紫杉醇治疗晚期胸腺瘤和胸腺癌的 II 期研究。
J Clin Oncol. 2011 May 20;29(15):2060-5. doi: 10.1200/JCO.2010.32.9607. Epub 2011 Apr 18.
9
Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus.血管内皮生长因子A(VEGF)及其受体(VEGFR1、2)在人胸腺正常及病理状态下的免疫组化表达
Ann Anat. 2008;190(3):238-45. doi: 10.1016/j.aanat.2007.05.003. Epub 2008 Feb 1.